Songling Zhang
Gynecologic Oncology Group(US)Jilin University(CN)Health Commission of Jilin Province(CN)First Affiliated Hospital of Xi'an Jiaotong University(CN)First Hospital of Jilin University(CN)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, CRISPR and Genetic Engineering, BRCA gene mutations in cancer, Ovarian cancer diagnosis and treatment, Cancer-related molecular mechanisms research
Most-Cited Works
- → Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial(2023)282 cited
- → Nrf2-mediated liver protection by esculentoside A against acetaminophen toxicity through the AMPK/Akt/GSK3β pathway(2016)126 cited
- → Nuclear-Encoded lncRNA MALAT1 Epigenetically Controls Metabolic Reprogramming in HCC Cells through the Mitophagy Pathway(2020)123 cited
- → Ubiquitination of the HPV Oncoprotein E6 Is Critical for E6/E6AP-Mediated p53 Degradation(2019)117 cited
- → Iron-Containing Protein-Mimic Supramolecular Iron Delivery Systems for Ferroptosis Tumor Therapy(2022)73 cited
- → Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial